Chinese inhibitor drug candidate becomes first to enter phase
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles
Hollywood star Shia LaBeouf is spotted on the streets of Gavin and Stacey's hometown Barry
Hollywood star Shia LaBeouf has shocked onlookers after being spotted on the streets of Barry in Wal2024-05-21In pictures: Auckland's Ramadan Night Markets in New Lynn
Mandy Asadpour, left, serves Iranian food at her Sepahan Kitchen stall. Photo: Supplied/ Pratik Nava2024-05-21VOX POPULI: LDP lawmakers’ remarks about political funds create a paradox
There exists a famous paradox involving a Cretan who claims, “Cretans always lie.”If we assume this2024-05-21Hong Kong waste levy to come into effect next April
The Hong Kong government will begin charging residents for rubbish disposal in April next year, mont2024-05-21A warrant for Netanyahu’s arrest was requested. But no decision was made about whether to issue it
CLAIM: The International Criminal Court issued an arrest warrant for Israeli Prime Minister Benjamin2024-05-21Shi Fu Miz 2023: Hong Kong music & art festival returns to Cheung Chau farm, expands to 3 days
Hong Kong’s boutique music and arts festival, Shi Fu Miz, is returning this October with its l2024-05-21
atest comment